Terns Pharmaceuticals’ decision to drop its liver disease ambitions may yet pay off, after the biotech posted phase 1 data ...

Terns Pharmaceuticals will advance TERN-601 into Phase II after early-stage data showed the oral therapy led to weight loss ...

Fatty liver disease linked to diabetes and obesity can easily progress to liver cirrhosis, but new research suggests that GLP ...

Novo Nordisk A/S's shares have stalled recently, but this looks like a natural digestion of gains from prior years. Click for ...

Why fork over thousands of dollars a month for prescription weight loss jabs when store-bought supplements claim to have the ...

As retail investors flock to Viking Therapeutics, the biotech firm is also catching the eye of billionaire fund managers like ...

The new Lemme GLP-1 Daily Capsules are being called an "Ozempic alternative." But do they really work — and if so, at what ...

Discover Citi's bullish outlook on Eli Lilly with a $1,060 target. Is now the time to invest? Find key insights and price ...

Eli Lilly and Company’s LLY stock has risen 21.1% in six months compared with an increase of 10.5% for the industry. The ...

Whether positive or negative, your mood may feel different on GLP-1 medications. Researchers share why that might be and how ...

The manufacturer of Ozempic is testing amycretin, an experimental weight-loss pill that appears to help people quickly shed ...

Here's what doctors think about them. Weight loss with Ozempic or Wegovy can be effective, but expensive. Enter so-called GLP-1 supplements that have taken on the nickname “nature’s Ozempic.” They’re ...